MacroGenics – HER2-positive Carcinoma

Access Program Information

The purpose of the Expanded Access program is to provide margetuximab to patients with
breast cancer and other HER2+ carcinomas who are not otherwise eligible for a MacroGenics
sponsored study and the potential benefit justifies the potential risk of treatment use.